ITGA4 and Increased total leukocyte count: ATL1102 treatment was as active as Natalizumab in reducing brain lesions in similar 12 week studies but did not show other hallmarks of CD49d cell surface blockade, such as leukocytosis attributed to interference of transmigration[23].